Crossmark

Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer

Crossref DOI link: https://doi.org/10.1186/s12943-024-02060-5

Published Online: 2024-08-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Dogra, Prashant

Shinglot, Vrushaly

Ruiz-Ramírez, Javier

Cave, Joseph

Butner, Joseph D.

Schiavone, Carmine

Duda, Dan G.

Kaseb, Ahmed O.

Chung, Caroline

Koay, Eugene J.

Cristini, Vittorio

Ozpolat, Bulent

Calin, George A.

Wang, Zhihui
Funding

Funding for this research was provided by:

National Institutes of Health (1R03EB033576, P50CA217674, P50CA217674, 1R01CA222007, 1R01CA222007, 1R01CA222007, 1R01CA222007)
License Information

Text and Data Mining valid from 2024-08-02

Version of Record valid from 2024-08-02
More Information

Article History

Received: 4 April 2024

Accepted: 4 July 2024

First Online: 2 August 2024

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below